NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

Core Viewpoint - NervGen Pharma Corp. announced the retirement of Chief Financial Officer Bill Adams, effective March 15, 2026, and has engaged an executive search firm to find a successor while Mr. Adams will continue to support the company in an advisory role post-retirement [1][2] Company Overview - NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions [3] - The company's mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself [3] - NervGen's lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvement in function, independence, and quality of life in clinical studies [3] Clinical Development - NVG-291 was evaluated in the Phase 1b/2a CONNECT SCI Study for individuals with chronic SCI, and the study demonstrated significant therapeutic potential [3] - The company is currently conducting an ongoing Phase 1b/2a CONNECT SCI Study for individuals with subacute SCI and is preparing for a Phase 3 clinical trial in chronic SCI [3] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI [3] Leadership Transition - Adam Rogers, President and CEO of NervGen, expressed gratitude for Bill Adams' leadership and contributions over the past six years, highlighting the company's transformation during his tenure [2] - Mr. Adams noted his pride in the financial and operational foundation built at NervGen and expressed confidence in the company's future [2]